AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$APGE

Dambkowski Carl sold (to issuer) $186K of APGE

Dambkowski Carl (Chief Medical Officer) sold (to issuer) 168,498 shares of Apogee Therapeutics, Inc. (APGE) at $135.06 ($0.19M total) across 2 trades over 2026-09-02 to 2026-09-03.

Original reporting
SEC EDGAR · Dambkowski Carl
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$APGE
Neutral
medium confidence
Mentioned
$APGE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$APGENeutralLow
01

Why it matters

The transaction is small and likely does not affect APGE's valuation.

02

Market read

Minor insider sale with limited trading relevance.

03

What to watch

Potential upcoming clinical data releases may outweigh insider sale impact.

Relevance 4/10Novelty 4/10Timing: filed Sep 3, 2026

Background

Form 4 disclosures are primary sources for insider transactions.

Company-level read

Ticker impact

$APGENeutralMedium confidence
Context

Chief Medical Officer sold all 168,498 shares for $185.7K in a Form 4 filing.

Expected impact

Minimal short‑term impact; market may view as neutral to slightly negative.

Evidence & confidence

The sale size is modest relative to market cap and does not constitute a material ownership change.

Market effects

Sector

None significant for biotech sector.

Regional

No regional effect.

Global

Limited to APGE shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move, not a negative signal.

Key entities

  • Person
    Dambkowski Carl

    Chief Medical Officer of Apogee Therapeutics

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

APGE insider trading history →

Related articles

SEP 9
$ABBVHighAI 9/10

Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth?

AbbVie (ABBV) completed its $10.9B acquisition of Apogee Therapeutics (APGE) at $135.11 per share. AbbVie also reported positive Phase 3 trial results for etentamig. Q2 2026 revenue for AbbVie rose 10.2% to $16.99B, with adjusted EPS up 22.9% to $3.65. Apogee reported a net loss of $85.9M in Q2 2026. Hedge funds increased stakes in both companies ahead of the deal.

insidermonkey.com3 min
SEP 3
$ABBVHighAI 9/10

AbbVie Completes $10.9 Bln Acquisition Of Apogee Therapeutics

AbbVie (ABBV) completed its $10.9 billion acquisition of Apogee Therapeutics (APGE), paying $135.11 per share. The deal strengthens AbbVie's immunology pipeline, including Apogee's lead asset, zumilokibart, for atopic dermatitis. AbbVie expects the acquisition to be dilutive to earnings until 2032. AbbVie reaffirmed its 2026 EPS guidance of $13.87-$14.07, including a $0.14 per-share dilutive impact. ABBV closed at $261.72, up 0.67%.

rttnews.com2 min
SEP 2
$MMEDMed

Biotech Stocks At 52-Week Highs - MMED +10%, PLSE, SOLV, RPRX, APGE

Several biotech stocks hit 52-week highs on September 1, 2026. MiniMed Group (MMED) rose 10% to $22.74 with 16.6% sales growth. Pulse Biosciences (PLSE) gained 3% to $54.39. Solventum (SOLV) reached $94.16 with 2.2% revenue growth. Royalty Pharma (RPRX) climbed to $62.58 with 14% royalty receipts growth. Apogee Therapeutics (APGE) hit $135.09 and will be acquired by AbbVie for $10.9B.

rttnews.com2 min